Topic
6 recent stories.
Policy / European Union
The European Medicines Agency's PRIME initiative aims to expedite the development and assessment of innovative treatments, focusing on medications addressing high unmet medical needs.
08 May 2026
Policy / European Union
Talmanco, a new generic medicine for pulmonary arterial hypertension (PAH), has been granted marketing authorization by the European Commission, providing an alternative treatment option for patients.
08 May 2026
Policy / European Union
Mysildecard, a generic form of sildenafil, has received EU approval for treating pulmonary arterial hypertension in both adults and children. The treatment aims to improve exercise capacity by dilating blood vessels in the lungs.
07 May 2026
Society / European Union
The European Commission has granted indefinite marketing authorization for Febuxostat Viatris, a generic medication indicated for treating high uric acid levels in gout sufferers and cancer patients undergoing chemotherapy. Approved since June 2017, the drug is recognized for its efficacy and safety profile, presenting a viable option within the region.
07 May 2026
Society / European Union
The European Medicines Agency has granted marketing authorisation for Atazanavir Viatris, a new generic HIV treatment that promises to be an effective option for patients aged 6 and over, particularly alongside low-dose ritonavir.
07 May 2026
Policy / European Union
Dovprela, an antibiotic for multidrug-resistant tuberculosis, has received standard authorisation from the European Medicines Agency, moving beyond its initial conditional approval.
07 May 2026